PDCD1 and hepatocellular carcinoma: From a translational perspective, the development of SF3B6 inhibitors, along with their potential synergistic effects when combined with existing therapies (e.g., sorafenib, PD-1 inhibitors, chemotherapy drugs), could substantially accelerate the progress of personalized therapeutic strategies for HCC.